Sionna Therapeutics, Inc. (NASDAQ:SION – Get Free Report)’s stock price reached a new 52-week high during mid-day trading on Monday . The company traded as high as $48.45 and last traded at $46.9930, with a volume of 196079 shares. The stock had previously closed at $44.23.
Wall Street Analyst Weigh In
A number of analysts have issued reports on SION shares. Wedbush initiated coverage on Sionna Therapeutics in a research note on Tuesday, May 5th. They issued an “outperform” rating and a $53.00 price objective on the stock. UBS Group reissued a “buy” rating on shares of Sionna Therapeutics in a research report on Monday, March 2nd. JonesTrading boosted their target price on Sionna Therapeutics from $52.00 to $63.00 and gave the company a “buy” rating in a research report on Tuesday, April 28th. Citigroup initiated coverage on Sionna Therapeutics in a research report on Tuesday, February 24th. They set an “outperform” rating on the stock. Finally, BTIG Research reissued a “buy” rating and set a $58.00 target price on shares of Sionna Therapeutics in a research report on Monday, April 27th. Three investment analysts have rated the stock with a Strong Buy rating, six have given a Buy rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $53.00.
Check Out Our Latest Stock Analysis on Sionna Therapeutics
Sionna Therapeutics Trading Up 3.9%
Sionna Therapeutics (NASDAQ:SION – Get Free Report) last announced its quarterly earnings data on Monday, March 2nd. The company reported ($0.46) EPS for the quarter, beating the consensus estimate of ($0.61) by $0.15. On average, equities analysts forecast that Sionna Therapeutics, Inc. will post -2.32 EPS for the current fiscal year.
Insider Buying and Selling at Sionna Therapeutics
In other news, Director Peter A. Thompson sold 235,863 shares of the company’s stock in a transaction that occurred on Wednesday, April 15th. The shares were sold at an average price of $44.64, for a total value of $10,528,924.32. Following the completion of the sale, the director owned 3,247,025 shares of the company’s stock, valued at approximately $144,947,196. This represents a 6.77% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Orbimed Advisors Llc sold 235,863 shares of the company’s stock in a transaction that occurred on Wednesday, April 15th. The stock was sold at an average price of $44.64, for a total transaction of $10,528,924.32. Following the completion of the sale, the director directly owned 3,247,025 shares of the company’s stock, valued at $144,947,196. The trade was a 6.77% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 1,131,856 shares of company stock worth $50,834,773 in the last ninety days. 3.90% of the stock is currently owned by corporate insiders.
Institutional Investors Weigh In On Sionna Therapeutics
Several hedge funds have recently modified their holdings of the business. GF Fund Management CO. LTD. bought a new stake in Sionna Therapeutics during the fourth quarter valued at about $36,000. Russell Investments Group Ltd. bought a new stake in Sionna Therapeutics during the third quarter valued at about $30,000. Balyasny Asset Management L.P. bought a new stake in Sionna Therapeutics during the fourth quarter valued at about $58,000. BNP Paribas Financial Markets bought a new stake in Sionna Therapeutics during the second quarter valued at about $31,000. Finally, Mirae Asset Global Investments Co. Ltd. bought a new stake in Sionna Therapeutics during the fourth quarter valued at about $89,000.
Sionna Therapeutics Company Profile
Sionna Therapeutics is a clinical-stage biotechnology company dedicated to developing next-generation RNA therapeutics for oncology and immunology indications. Leveraging proprietary lipid nanoparticle and coacervate delivery technologies, the company aims to overcome key challenges associated with stability, targeting and immune activation that have historically limited the clinical performance of mRNA-based medicines. Its strategic focus spans both solid tumors and hematological malignancies, as well as selected autoimmune disorders, reflecting a broad ambition to harness the power of messenger RNA in diverse therapeutic areas.
At the heart of Sionna’s approach is a platform that combines optimized ionizable lipids with bespoke surface chemistries to enhance payload delivery, intracellular release and endosomal escape.
Featured Articles
- Five stocks we like better than Sionna Therapeutics
- Before the Moon Base Gets Built, These 4 Companies Win
- Industrial Buybacks: Top Homebuilding Supplier Leads Buyback Increases
- 3 Stocks That Win If Inflation Surprises to the Downside
- MercadoLibre Boldly Invests in Growth: Discount Deepens
Receive News & Ratings for Sionna Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sionna Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
